Criterium, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1991-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.criteriuminc.com
Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- Drug: Fruquintinib+ Lonsurf (trifluridine and tipiracil)
- First Posted Date
- 2025-05-28
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06992258
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
- Conditions
- Breast CancerPretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05458674
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸George Washington Medical Faculty Associates, Washington, District of Columbia, United States
🇺🇸New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
- Conditions
- HER2-positive Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05230810
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Cancer Care & Hematology-Fort Collins, Fort Collins, Colorado, United States
🇺🇸Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States
A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Criterium, Inc.
- Registration Number
- NCT05180422
- Locations
- 🇺🇸
Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT04791384
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Duke Cancer Center, Durham, North Carolina, United States
🇺🇸Cancer Care Northwest, Spokane Valley, Washington, United States
- Prev
- 1
- 2
- 3
- Next